---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008972"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:56:05.945561+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Janux Q1 net loss $13.4M; cash $361.2M; IND filed for JANX007

## Summary
- Net loss of $13.4M for Q1 2022 vs. $2.3M in Q1 2021; R&D spend $10.2M, G&A $4.9M.
- Cash & investments $361.2M at March 31, 2022, down from $375.0M at Dec 31, 2021.
- IND submitted for PSMA-TRACTr (JANX007); IND for EGFR-TRACTr (JANX008) expected 2H 2022.
- Merck nominated a second target under the 2020 collaboration agreement in May 2022.

## SEC filing metadata
- accession: 0000950170-22-008972
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017022008972/0000950170-22-008972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017022008972/janx-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008972
- JSON: https://secwatch.observer/filing/0000950170-22-008972.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008972.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.